Immupharma Share Discussion Threads

[nobbygnome] 08/1/2019 20:57

Thanks for that erudite, informative post!

I want to get Lupuzor to patients in a format where it actually has a chance of working. The drug does have some pharmacological activity if used in the right way at the right dose. Currently the incompetent management are pursuing a course which is giving the drug no chance of being efficacious....and in the process are wasting time and money. That is the reality, which will be proved over the next year or so. A slow car crash is unraveling.....

[nobbygnome] 07/1/2019 21:14

LOL. I thought it was a free country where we have free speech so I will comment whenever I like!

You shareholders should be agitating for change because the management led by lyin Tim are slowly wasting your money to get absolutely nowhere. Incompetence is the word......

[youngharry2] 07/1/2019 20:53

Nobby
Raging about any matter, an individual or a company, is simply bad for your health. It does absolutely no harm to the target of your ire whatsoever. My advice to you is to seek therapy, it'll do the world of good and of course spare the rest of us from your relentless rants about IMM, Tim and so on.

[youngharry2] 07/1/2019 20:49

Colsmith
Suggest you send your ideas to DD at [e-mail]

[colsmith] 20/12/2018 10:05

Bearing in mind the charge of western companies to China I would have thought IMM would be at least seeing that market as an opportunity to get collaboration with a local Pharma. The smoke signals of (tragically) high prevalence of the disease and lots of cash in China would seem an obvious one to pursue and even a 49 v 51 % stake would be enticing just GM et all see as worthwhile.

[brad44] 20/12/2018 09:09

i really cannot see the purpose of your post other than to goad or gloat, so well said s-k

[sicilian_kan] 20/12/2018 09:06

True, but the terms look poor. Low milestones and unspecified royalties from what I can see.

[nobbygnome] 20/12/2018 08:58

LOL.....but SAR do own part of a drug which is looking good in trials.....although the proof of the pudding will be in the eating as always! Of course they are not doing the trials which increases the chance of success!

[sicilian_kan] 20/12/2018 08:54

Hi Nobby, bit rich that from Sareum shareholders...

[nobbygnome] 19/12/2018 14:16

The Lupuzor trial result was much discussed at the Sareum AGM yesterday. I think it is fair to say that IMM are the laughing stock of their peer companies in this sector.

[colsmith] 18/12/2018 17:23

Guys, having seen the news piece I posted above I had a look to see if Lupus is a significant malady in China. Found this below which I guess could suggest the company think about a P3 type or MAP activity in China?

------------------------
Lupus, an autoimmune disease involving multiple organs, is believed to disproportionately affect patients in Asian countries, with higher incidences and greater severity.

In China, “the estimated prevalence of SLE was 50-100 cases per 100,000 persons, which was much higher than that of 10-35 per 100,000 people in European and North American countries,” the researchers wrote.

[colsmith] 18/12/2018 14:03

Looks like China is moving in other directions before the West.


--------------------
In the case of roxadustat, Beijing allowed AstraZeneca and Fibrogen to submit their clinical trial results to the regulator on a rolling basis starting last year, rather than waiting for all their key clinical trials to finish. The Chinese regulator also awarded priority review status, accelerating its assessment of the drug. Roxadustat is aimed at patients on dialysis who are suffering from anemia caused by chronic kidney disease.

The approval came just two months after the companies completed their submission. The companies haven't yet submitted the drug to the U.S. Food and Drug Administration, though plan to do so next year. It is unusual for drug companies to seek approval in China before the U.S., which is the world's biggest pharmaceuticals market

[stockriser] 17/12/2018 07:25

Well that ticks a big box ;-)

GLASR

[kirk 6] 17/12/2018 07:08

Immupharma PLC Appointment of Nominated AdviserSource: UK Regulatory (RNS & others)TIDMIMMRNS Number : 5484KImmupharma PLC17 December 201817 December 2018ImmuPharma PLC("ImmuPharma" or the "Company")APPOINTMENT OF NOMINATED ADVISORImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to announce the appointment of SPARK Advisory Partners Limited ("SPARK") as the Company's Nominated Advisor ("NOMAD"), with immediate effect.Commenting on the appointment, ImmuPharma's Chairman, Tim McCarthy, said:"I am delighted to announce the appointment of SPARK as the Company's NOMAD. We look forward to working with the team going forward, alongside our joint brokers, Stanford Capital Partners and SI Capital."This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR") For further information please contact: ImmuPharma plc (www.immupharma.com) + 44 (0) 207 152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD) Neil Baldwin [phone] Vassil Kirtchev Stanford Capital Partners (Joint Broker) Patrick Claridge, John Howes [phone] SI Capital (Joint Broker) Nick Emerson [phone] About SPARK Advisory Partners Limited SPARK Advisory Partners was established in January 2012 by its founding partners to provide product independent corporate finance advice to mid-market companies, owner managers and shareholders. SPARK is owned by its partners who have worked together for many years. The team has a broad cross section of skills and transaction experience, encompassing M&A, private equity, public capital raisings and debt advisory services. For more information go to: www.sparkadvisorypartners.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.ENDAPPBBBDDCBBBGIS(END) Dow Jones NewswiresDecember 17, 2018 02:01 ET (07:01 GMT)

[ken chung] 07/12/2018 08:24

Another placing before the next results on Q3 on the failed drug. Lemmings and mushrooms only now.

[nobbygnome] 07/12/2018 08:10

Go on, tell me which parts constitutes a 'pretty good update'?

[kirk 6] 07/12/2018 07:52

Eh no one ever said that ? Your just talking to yourself mate.Fact is there is a lot of uncertainty around the nomad and this should put it to bed. That's all simple as that

[nobbygnome] 07/12/2018 07:47

The early bird catches the worm...... Point out to me which part exactly constitutes a 'pretty good update'?

If a company can't sort out a new Nomad, that is a sorry state of affairs ....

[kirk 6] 07/12/2018 07:44

Pretty good update and this could well put all the uncertainty to bed:"With active discussions ongoing regarding the appointment of a new NOMAD, we look forward to updating the market and shareholders again in the near future."

[kirk 6] 07/12/2018 07:43

Yet you have to be the first to comment lol sad

[nobbygnome] 07/12/2018 07:34

Well a completely nothing announcement this morning; no wonder they put it out on a Friday. But never mind, the board will keep on taking their big salaries wasting your shareholder funds whilst doing virtually nothing. You shareholder should be agitating for changes on the board and some real action.

It is all so sad....and predictable!